Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement
June 25, 2015 at 07:01 AM EDT
Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) today announced pre-treatment biomarker and histology data from the first 16 patients ...
